Key result
The PROVE/HF registry was successfully designed and implemented across 18 cardiac centers in Iran, utilizing a 27-item questionnaire to collect comprehensive data on heart failure patients.
Why the study?
Heart failure imposes an increasing prevalence and economic burden, yet registries for its management are less frequently conducted.
Observational
Yes
The PROVE/HF registry establishes a comprehensive, multicenter database for heart failure patients in Iran to improve disease management and facilitate future research.
PROVE HF registry launched in Iran; leaves open systematic data collection for future observational research and quality initiatives.
BACKGROUND: Heart failure (HF) resulted from ultimate pathway of many cardiovascular diseases (CVDs) or as a separate entity poses a considerable increasing prevalence and economic burden, but its registry for better management is less frequently done. In this study, we aimed to design and implement HF registry. METHODS: Persian Registry Of cardioVascular diseasE (PROVE) was initiated from March 2015 and continuously collected information of patients suffering from HF, ST-elevation myocardial infarction (STEMI), atrial fibrillation (AF), percutaneous coronary intervention (PCI), stroke, familial hypercholesterolemia (FH), congenital heart disease (CHD), chronic ischemic cardiovascular disease (CICD), and acute coronary syndrome (ACS) from 18 different cardiac centers. Data of patients with HF were collected from their medical forms and recorded in a registry system of PROVE/HF plus telephone follow-up survey of 1, 6, and 12 months after the date of HF attack. RESULTS: Assessment of all related questions led to definition of a final questionnaire including 27 items regarding demographic information, underlying disorders and their complications, patients' symptoms and signs, and laboratory and relevant para-clinic data at admission time, during hospitalization, and post discharge. Follow-up information was mostly based on patients' general status and medication usage. CONCLUSION: PROVE execution was a successful and hopeful project providing data of major CVDs in order to design appropriate preventive actions and better management and treatment strategies plus a valuable data center being utilized in multiple future comprehensive projects.
No takes yet. Share an insight, caveat, or question.
Givi et al. (2019) conducted an observational in Heart failure. PROVE/HF registry implementation was evaluated on Development of a final questionnaire and registry methodology. The PROVE/HF registry was successfully designed and implemented across 18 cardiac centers in Iran, utilizing a 27-item questionnaire to collect comprehensive data on heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: